© Reuters.
MARLBOROUGH, Mass. – Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company focused on immuno-oncology, has announced the addition of three new clinical trial sites for its Phase 1b study of PH-762, a gene silencing technology aimed at enhancing the effectiveness of immune cells in destroying tumor cells. These sites are The George Washington University Medical Faculty Associates in Washington, D.C., Banner (NASDAQ:) MD Anderson Cancer Center in Gilbert, Arizona, and Integrity Research Clinical Associates in Delray Beach, Florida.
The company’s PH-762 is an INTASYL compound designed to silence PD-1, a protein that can inhibit T cells from killing cancer cells. The ongoing trial is assessing the safety, tolerability, and tumor response of PH-762 when injected into tumors of adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The goal is also to determine the appropriate dose for further studies.
Phio’s CEO, Robert Bitterman, expressed enthusiasm about the expansion, highlighting the added sites’ reputations in conducting skin cancer trials and their contribution to broader patient inclusion. The first patient in this study was enrolled at Centricity Research in Dublin, Ohio, in November.
The clinical trial is non-comparative, focusing on neoadjuvant monotherapy with PH-762. Further details are available on clinicaltrials.gov under identifier NCT06014086.
Phio Pharmaceuticals specializes in proprietary INTASYL siRNA gene silencing technology, which is unique in the self-delivering RNAi technology space, targeting proteins that reduce the body’s ability to fight cancer without the need for complex delivery systems.
This press release contains forward-looking statements regarding the potential of PH-762 to treat certain types of skin cancer. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ. Phio does not commit to updating any forward-looking statements post-release. The information reported is based on a press release statement from Phio Pharmaceuticals Corp.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
